Morgan Stanley
CGEM icon

Morgan Stanley’s Cullinan Oncology CGEM Stock Holding History

Morgan Stanley’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.38M Sell
589,483
-177,451
-23% -$2.28M ﹤0.01% 3713
2025
Q4 		$7.94M Buy
766,934
+366,780
+92% +$3.31M ﹤0.01% 3808
2025
Q3 		$2.37M Buy
400,154
+158,062
+65% +$1.16M ﹤0.01% 4678
2025
Q2 		$1.82M Sell
242,092
-239,740
-50% -$1.93M ﹤0.01% 4762
2025
Q1 		$3.65M Sell
481,832
-156,237
-24% -$1.5M ﹤0.01% 4191
2024
Q4 		$7.77M Sell
638,069
-35,303
-5% -$507K ﹤0.01% 3615
2024
Q3 		$11.3M Sell
673,372
-164,911
-20% -$2.93M ﹤0.01% 3339
2024
Q2 		$14.6M Sell
838,283
-314,361
-27% -$6.69M ﹤0.01% 2996
2024
Q1 		$19.6M Sell
1,152,644
-687,154
-37% -$10.6M ﹤0.01% 2709
2023
Q4 		$18.7M Buy
1,839,798
+1,556,382
+549% +$13.8M ﹤0.01% 3403
2023
Q3 		$2.56M Sell
283,416
-41,671
-13% -$434K ﹤0.01% 4231
2023
Q2 		$3.5M Buy
325,087
+159,139
+96% +$1.69M ﹤0.01% 4028
2023
Q1 		$1.7M Sell
165,948
-59,070
-26% -$651K ﹤0.01% 4555
2022
Q4 		$2.37M Sell
225,018
-63,262
-22% -$768K ﹤0.01% 4338
2022
Q3 		$3.7M Sell
288,280
-57,263
-17% -$772K ﹤0.01% 3942
2022
Q2 		$4.43M Sell
345,543
-152,332
-31% -$1.73M ﹤0.01% 3870
2022
Q1 		$5.21M Buy
497,875
+168,419
+51% +$2.28M ﹤0.01% 3647
2021
Q4 		$5.08M Buy
329,456
+258,657
+365% +$5.16M ﹤0.01% 3707
2021
Q3 		$1.6M Buy
70,799
+4,450
+7% +$119K ﹤0.01% 4746
2021
Q2 		$1.71M Buy
66,349
+65,964
+17,134% +$2.03M ﹤0.01% 4750
2021
Q1 		$16K Buy
+385
New +$15.6K ﹤0.01% 6793

Other funds holding CGEM

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Morgan Stanley's CGEM Position: Q1 2026 in Review

Morgan Stanley reduced its Cullinan Oncology (CGEM) stake by 23% in Q1 2026, selling an estimated $2.28M and leaving 589,483 shares worth $8.38M. The position accounts for ﹤0.01% of the portfolio, ranked #3713.

Morgan Stanley first reported a position in CGEM in Q1 2021 and has held it in 21 quarters since. The position peaked at $19.6M in Q1 2024. 174 funds tracked by Wall St. Rank hold CGEM as of Q1 2026.

  • Morgan Stanley held 589,483 shares of Cullinan Oncology worth $8.38M as of Q1 2026.
  • Morgan Stanley sold 177,451 Cullinan Oncology shares in Q1 2026, an estimated $2.28M.
  • Cullinan Oncology made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #3713 holding.
  • Morgan Stanley first reported a position in Cullinan Oncology in Q1 2021 and has held it in 21 quarters since.
  • Morgan Stanley's Cullinan Oncology position peaked at $19.6M in Q1 2024.
  • 174 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.